- Home
- KPRX vs AMBO Comparison
KPRX vs AMBO Comparison
Compare KPRX & AMBO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPRX
- AMBO
- Stock Information
- Founded
- KPRX 1998
- AMBO 2000
- Country
- KPRX United States
- AMBO United States
- Employees
- KPRX N/A
- AMBO N/A
- Industry
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- AMBO Other Consumer Services
- Sector
- KPRX Health Care
- AMBO Real Estate
- Exchange
- KPRX Nasdaq
- AMBO Nasdaq
- Market Cap
- KPRX 9.2M
- AMBO 10.5M
- IPO Year
- KPRX N/A
- AMBO 2010
- Fundamental
- Price
- KPRX $2.65
- AMBO $3.73
- Analyst Decision
- KPRX Strong Buy
- AMBO
- Analyst Count
- KPRX 1
- AMBO 0
- Target Price
- KPRX $10.00
- AMBO N/A
- AVG Volume (30 Days)
- KPRX 32.4K
- AMBO 26.9K
- Earning Date
- KPRX 11-07-2025
- AMBO 08-05-2025
- Dividend Yield
- KPRX N/A
- AMBO N/A
- EPS Growth
- KPRX N/A
- AMBO N/A
- EPS
- KPRX N/A
- AMBO 0.69
- Revenue
- KPRX N/A
- AMBO $9,699,000.00
- Revenue This Year
- KPRX N/A
- AMBO N/A
- Revenue Next Year
- KPRX N/A
- AMBO N/A
- P/E Ratio
- KPRX N/A
- AMBO $5.35
- Revenue Growth
- KPRX N/A
- AMBO 23.73
- 52 Week Low
- KPRX $2.25
- AMBO $1.00
- 52 Week High
- KPRX $4.18
- AMBO $5.55
- Technical
- Relative Strength Index (RSI)
- KPRX 46.53
- AMBO 59.35
- Support Level
- KPRX $2.60
- AMBO $2.91
- Resistance Level
- KPRX $2.80
- AMBO $3.80
- Average True Range (ATR)
- KPRX 0.11
- AMBO 0.36
- MACD
- KPRX -0.01
- AMBO 0.01
- Stochastic Oscillator
- KPRX 21.21
- AMBO 91.11
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
About AMBO Ambow Education Holding Ltd.
Ambow Education Holding Ltd is an AI-driven technology educational company. Along with its subsidiaries, the company is developing a new HybriU AI Digital Education Solution that transforms the educational environment, bridging the gap between traditional methods and the future of digital learning. The solution combines sophisticated software and hardware to create an AI-powered digital and hybrid classroom, designed to enhance educational delivery and engagement. In addition, the group offers high-quality, individualized, and dynamic career education services and products through the operation of its for-profit colleges. Substantially the majority of the group's revenues are derived from the United States, based on the geographical locations where services are provided to customers.